Cargando…

Measuring the functional impact of cognitive impairment in Huntington’s disease

BACKGROUND: Patients with Huntington’s disease (HD) exhibit a variable predominance of cognitive, behavioral and motor symptoms. A specific instrument focusing on the impact of cognitive impairment in HD over functional capacity is lacking. OBJECTIVE: To address the need for a brief and specifically...

Descripción completa

Detalles Bibliográficos
Autores principales: Horta-Barba, Andrea, Martínez-Horta, Saül, Pérez-Pérez, Jesus, Sampedro, Frederic, Puig-Davi, Arnau, Pagonabarraga, Javier, Kulisevsky, Jaime
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9217879/
https://www.ncbi.nlm.nih.gov/pubmed/35061089
http://dx.doi.org/10.1007/s00415-021-10955-2
_version_ 1784731755427659776
author Horta-Barba, Andrea
Martínez-Horta, Saül
Pérez-Pérez, Jesus
Sampedro, Frederic
Puig-Davi, Arnau
Pagonabarraga, Javier
Kulisevsky, Jaime
author_facet Horta-Barba, Andrea
Martínez-Horta, Saül
Pérez-Pérez, Jesus
Sampedro, Frederic
Puig-Davi, Arnau
Pagonabarraga, Javier
Kulisevsky, Jaime
author_sort Horta-Barba, Andrea
collection PubMed
description BACKGROUND: Patients with Huntington’s disease (HD) exhibit a variable predominance of cognitive, behavioral and motor symptoms. A specific instrument focusing on the impact of cognitive impairment in HD over functional capacity is lacking. OBJECTIVE: To address the need for a brief and specifically developed HD questionnaire able to capture functional aspects suspected to be sensitive to cognitive impairment. METHODS: We developed and validated the “Huntington’s Disease-Cognitive Functional Rating Scale” (HD-CFRS) in 78 symptomatic carriers of the Huntington’s disease mutation. We also administered the HD-CFRS to a knowledgeable informant to measure the level of agreement. To explore the association between HD-CFRS scores and participants’ cognitive status, we administered objective measures of cognition. Participants were classified as cognitively preserved (HD-NC), as having mild cognitive impairment (HD-MCI), or as having dementia (HD-Dem). RESULTS: The HD-CFRS showed concurrent validity and internal consistency in the three groups. HD carriers and informants in the HD-NC group obtained similar HD-CFRS scores. However, in patients with mild cognitive impairment and dementia, informers reported greater functional impairment than HD participants. The HD-CFRS total score showed strong correlations with measures assessing cognition. CONCLUSIONS: These findings support the utility of the HD-CFRS as a brief and reliable instrument to measure functional defects associated with cognitive impairment in HD. We believe this questionnaire could be a useful tool both for clinical practice and research.
format Online
Article
Text
id pubmed-9217879
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-92178792022-06-24 Measuring the functional impact of cognitive impairment in Huntington’s disease Horta-Barba, Andrea Martínez-Horta, Saül Pérez-Pérez, Jesus Sampedro, Frederic Puig-Davi, Arnau Pagonabarraga, Javier Kulisevsky, Jaime J Neurol Original Communication BACKGROUND: Patients with Huntington’s disease (HD) exhibit a variable predominance of cognitive, behavioral and motor symptoms. A specific instrument focusing on the impact of cognitive impairment in HD over functional capacity is lacking. OBJECTIVE: To address the need for a brief and specifically developed HD questionnaire able to capture functional aspects suspected to be sensitive to cognitive impairment. METHODS: We developed and validated the “Huntington’s Disease-Cognitive Functional Rating Scale” (HD-CFRS) in 78 symptomatic carriers of the Huntington’s disease mutation. We also administered the HD-CFRS to a knowledgeable informant to measure the level of agreement. To explore the association between HD-CFRS scores and participants’ cognitive status, we administered objective measures of cognition. Participants were classified as cognitively preserved (HD-NC), as having mild cognitive impairment (HD-MCI), or as having dementia (HD-Dem). RESULTS: The HD-CFRS showed concurrent validity and internal consistency in the three groups. HD carriers and informants in the HD-NC group obtained similar HD-CFRS scores. However, in patients with mild cognitive impairment and dementia, informers reported greater functional impairment than HD participants. The HD-CFRS total score showed strong correlations with measures assessing cognition. CONCLUSIONS: These findings support the utility of the HD-CFRS as a brief and reliable instrument to measure functional defects associated with cognitive impairment in HD. We believe this questionnaire could be a useful tool both for clinical practice and research. Springer Berlin Heidelberg 2022-01-21 2022 /pmc/articles/PMC9217879/ /pubmed/35061089 http://dx.doi.org/10.1007/s00415-021-10955-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Communication
Horta-Barba, Andrea
Martínez-Horta, Saül
Pérez-Pérez, Jesus
Sampedro, Frederic
Puig-Davi, Arnau
Pagonabarraga, Javier
Kulisevsky, Jaime
Measuring the functional impact of cognitive impairment in Huntington’s disease
title Measuring the functional impact of cognitive impairment in Huntington’s disease
title_full Measuring the functional impact of cognitive impairment in Huntington’s disease
title_fullStr Measuring the functional impact of cognitive impairment in Huntington’s disease
title_full_unstemmed Measuring the functional impact of cognitive impairment in Huntington’s disease
title_short Measuring the functional impact of cognitive impairment in Huntington’s disease
title_sort measuring the functional impact of cognitive impairment in huntington’s disease
topic Original Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9217879/
https://www.ncbi.nlm.nih.gov/pubmed/35061089
http://dx.doi.org/10.1007/s00415-021-10955-2
work_keys_str_mv AT hortabarbaandrea measuringthefunctionalimpactofcognitiveimpairmentinhuntingtonsdisease
AT martinezhortasaul measuringthefunctionalimpactofcognitiveimpairmentinhuntingtonsdisease
AT perezperezjesus measuringthefunctionalimpactofcognitiveimpairmentinhuntingtonsdisease
AT sampedrofrederic measuringthefunctionalimpactofcognitiveimpairmentinhuntingtonsdisease
AT puigdaviarnau measuringthefunctionalimpactofcognitiveimpairmentinhuntingtonsdisease
AT pagonabarragajavier measuringthefunctionalimpactofcognitiveimpairmentinhuntingtonsdisease
AT kulisevskyjaime measuringthefunctionalimpactofcognitiveimpairmentinhuntingtonsdisease